CAPTURE: C7E3 Fab Anti-Platelet Therapy in Unstable REfractory Angina
Study Population: Patients with chest pain at rest and ECG signs of UA (NQMI excluded) proven refractory to 2-48 hours of heparin and nitroglycerin and determined eligible via diagnostic catheterization for PCI within 18-24 hours
Dosing arms: ASA + standard-dose, weight-adjusted heparin - abciximab 0.25 mg/kg bolus + 10 μg/min infusion for 18-24 hours pre-PCI and 1 hour post-PCI (n=630) - placebo (n=635)
Primary endpoint: Death, MI, or urgent repeat intervention at 30 days
The CAPTURE Investigators. Lancet. 1997; 349: 1429-1435.
CAPTURE Study design
heparin + nitroglycerin
Diagnosis of UA
Chest pain with ECG signs of ischemia (non-Q-wave MI excluded)
2 - 48 hours
ASA + heparin + abciximab
Diagnosis of refractory UA
Chest pain with ECG signs of ischemia with heparin + nitroglycerin
Diagnostic catheterization confirming eligibility for PCI
PCI
18 - 24 hours
pre-PCI
1 hour
post-PCI
The CAPTURE Investigators. Lancet. 1997; 349: 1429-1435.
CAPTURE Efficacy results summary
Endpoint
Death, MI, or urgent repeat intervention Death, MI, or any revascularization Death MI Urgent repeat intervention
Any revascularization
Time 30 days
6 months 30 days 6 months Pre-PCI 30 days 6 months 30 days 6 months
Placebo (n=635) 15.9%
30.8% 1.3% 2.2% 2.1% 8.2% 9.3%
10.9% 24.9%
Abciximab (n=630) 11.3%
31.0% 1.0% 2.8% 0.6% 4.1% 6.6%
7.8% 25.4%
P value vs placebo 0.012
ns ns ns 0.029 0.002 ns
ns ns
The CAPTURE Investigators. Lancet. 1997; 349: 1429-1435.
Safety endpoint
Major TIMI bleeding Minor TIMI bleeding Platelet count < 100,000/mm3
Placebo (n=635)
1.9% 2.0% 1.3%
Abciximab (n=630)
3.8% 4.8% 5.6%
CAPTURE Safety results summary
The CAPTURE Investigators. Lancet. 1997; 349: 1429-1435.